跳至主要内容
临床试验/NCT01395069
NCT01395069已完成4 期

Randomized Clinical Trial Comparing Prophylactic Nepafenac 0.1% and Ketorolac 0.5% Versus Placebo in Preventing Postoperative Macular Edema After Uncomplicated Phacoemulsification Cataract Extraction (PNK)

Queen's University1 个研究点 分布在 1 个国家目标入组 162 人开始时间: 2010年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
162
试验地点
1
主要终点
Change in macular volume (as quantified by OCT) at one month (compared to baseline)

研究概览

简要总结

Assess prophylactic efficacy of topical non-steroidal anti-inflammatory drops in preventing macular edema. Patient undergoing uncomplicated cataract surgery will be enrolled and randomized to nepafenac, ketorolac, or placebo. Follow-up will occur at 1 month with ocular coherence tomography (OCT).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability to give informed consent
  • Age 18 years and older

排除标准

  • Any pre-existing retinal disease (e.g., diabetic retinopathy, vein occlusion, exudative macular degeneration, etc.)
  • Previous uveitis
  • Previous intraocular surgery
  • Allergy or hypersensitivity to NSAIDs
  • Complicated cataract surgery

研究组 & 干预措施

Nepafenac 0.1%

Active Comparator

干预措施: Nepafenac 0.1% (Drug)

Ketorolac 0.5%

Active Comparator

干预措施: Ketorolac 0.5% (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (sterile saline drops) (Other)

结局指标

主要结局

Change in macular volume (as quantified by OCT) at one month (compared to baseline)

时间窗: baseline and one month after surgery

次要结局

  • COMTOL health-related quality-of-life(one month after surgery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Sherif R El-Defrawy

Principal Investigator

Queen's University

研究点 (1)

Loading locations...

相似试验